NAFL
MCID: NNL005
MIFTS: 62

Non-Alcoholic Fatty Liver Disease (NAFL)

Categories: Cancer diseases, Cardiovascular diseases, Genetic diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Non-Alcoholic Fatty Liver Disease

MalaCards integrated aliases for Non-Alcoholic Fatty Liver Disease:

Name: Non-Alcoholic Fatty Liver Disease 12 25 17
Nonalcoholic Fatty Liver Disease 25 36 15
Non-Alcoholic Fatty Liver 12 17
Fatty Liver 25 54
Steatosis 25 17
Nafld 12 25
Susceptibility to Nonalcoholic Fatty Liver Disease 6
Non-Alcoholic Steatohepatitis 25
Nonalcoholic Steatohepatitis 25
Nafl 12
Nash 25

Classifications:



External Ids:

Disease Ontology 12 DOID:0080208 DOID:0080546
KEGG 36 H01333

Summaries for Non-Alcoholic Fatty Liver Disease

Genetics Home Reference : 25 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat. The fat deposits in the liver associated with NAFLD usually cause no symptoms, although they may cause increased levels of liver enzymes that are detected in routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged. Between 7 and 30 percent of people with NAFLD develop inflammation of the liver (non-alcoholic steatohepatitis, also known as NASH), leading to liver damage. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue (fibrosis), resulting in irreversible liver disease (cirrhosis) that causes the liver to stop working properly. Signs and symptoms of cirrhosis, which get worse as fibrosis affects more of the liver, include fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), and yellowing of the skin and whites of the eyes (jaundice). Scarring in the vein that carries blood into the liver from the other digestive organs (the portal vein) can lead to increased pressure in that blood vessel (portal hypertension), resulting in swollen blood vessels (varices) within the digestive system. Rupture of these varices can cause life-threatening bleeding. NAFLD and NASH are thought to account for many cases of cirrhosis that have no obvious underlying cause (cryptogenic cirrhosis); at least one-third of people with NASH eventually develop cirrhosis. People with NAFLD, NASH, and cirrhosis are also at increased risk of developing liver cancer (hepatocellular cancer). NAFLD is most common in middle-aged or older people, although younger people, including children, are also affected. It is often considered as part of a group of conditions known collectively as the metabolic syndrome; in addition to NAFLD, the metabolic syndrome includes obesity, type 2 diabetes or pre-diabetes (insulin resistance), high levels of fats (lipids) such as cholesterol and triglycerides in the blood, and high blood pressure (hypertension). However, a person with NAFLD may not have all or any of the other conditions that make up the metabolic syndrome, and individuals with some or all of those conditions may not have NAFLD.

MalaCards based summary : Non-Alcoholic Fatty Liver Disease, also known as nonalcoholic fatty liver disease, is related to body mass index quantitative trait locus 11 and overnutrition. An important gene associated with Non-Alcoholic Fatty Liver Disease is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Non-alcoholic fatty liver disease (NAFLD) and Glycerolipid metabolism. The drugs Losartan and Milk thistle have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart.

Disease Ontology : 12 A fatty liver disease characterized by the storing of excess fat in liver cells which is not caused by heavy alcohol use.

KEGG : 36 It has been reported that those patients with nonalcoholic fatty liver disease (NAFLD) are probably more common in those individuals with metabolic syndrome, which includes obesity and type 2 diabetes mellitus. The spectrum of NAFLD ranges from simple steatosis to steatohepatitis with hepatic inflammation and fibrosis, known as nonalcoholic steatohepatitis (NASH). Of those with NASH, approximately 20% will go on to develop cirrhosis and hepatocellular carcinoma.

Wikipedia : 74 Non-alcoholic fatty liver disease (NAFLD) is excessive fat build-up in the liver with insulin resistance... more...

Related Diseases for Non-Alcoholic Fatty Liver Disease

Diseases related to Non-Alcoholic Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 875)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 11 31.5 PNPLA3 MIR378A MIR34A MIR27B MIR22 MIR21
2 overnutrition 31.3 MIR378A MIR34A MIR22 MIR21 MIR140 MIR122
3 arteries, anomalies of 31.2 MIR34A MIR33A MIR29C MIR27B MIR27A MIR22
4 hepatocellular carcinoma 31.1 PNPLA3 MIR34A MIR27A MIR26A1 MIR22 MIR21
5 inherited metabolic disorder 30.7 PNPLA3 MIR33A MIR21
6 biliary tract disease 30.7 MIR378A MIR200A MIR140
7 lipid storage disease 30.7 PNPLA3 MIR22 MIR122
8 acquired metabolic disease 30.6 MIR378A MIR27A MIR22 MIR21 MIR200A MIR140
9 renal fibrosis 30.5 MIR29C MIR21 MIR200B
10 glucose metabolism disease 30.5 MIR22 MIR21 MIR140 MIR10B
11 muscular dystrophy, duchenne type 30.2 MIR34A MIR29C MIR22 MIR21
12 large intestine cancer 30.2 MIR378A MIR34A MIR29C MIR27B MIR27A MIR22
13 disease of mental health 30.2 MIR22 MIR21 MIR140 MIR132
14 gastric cancer 30.1 MIR34A MIR29C MIR27B MIR27A MIR22 MIR21
15 lymphoma, non-hodgkin, familial 30.1 MIR34A MIR27A MIR21 MIR200B MIR140
16 intestinal disease 30.1 MIR378A MIR34A MIR29C MIR27B MIR27A MIR22
17 pancreas disease 30.0 MIR34A MIR33A MIR27B MIR27A MIR21 MIR200A
18 prostate disease 30.0 MIR34A MIR27A MIR26A1 MIR22 MIR21 MIR200B
19 lymphoma, hodgkin, classic 30.0 MIR21 MIR200A MIR140
20 gastrointestinal system disease 29.4 MIR378A MIR34A MIR29C MIR27B MIR27A MIR26A1
21 lung cancer susceptibility 3 29.2 MIR29C MIR21 MIR200B MIR200A MIR140
22 lung cancer 29.0 MIR378A MIR34A MIR33A MIR29C MIR27B MIR27A
23 ovarian cancer 28.9 MIR34A MIR29C MIR27A MIR22 MIR21 MIR200B
24 fatty liver disease, nonalcoholic 2 12.6
25 fatty liver disease, nonalcoholic 1 12.5
26 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 12.4
27 non-alcoholic steatohepatitis 12.2
28 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.2
29 hypertriglyceridemia, transient infantile 12.1
30 lipodystrophy, familial partial, type 2 11.9
31 liver disease 11.8
32 fatty liver disease 11.8
33 reye syndrome 11.7
34 congenital generalized lipodystrophy 11.4
35 familial partial lipodystrophy 11.4
36 mitochondrial dna depletion syndrome 4a 11.4
37 adrenomyodystrophy 11.4
38 visceral steatosis, congenital 11.4
39 corticosteroid-binding globulin deficiency 11.2
40 lipodystrophy, congenital generalized, type 2 11.2
41 3-methylglutaconic aciduria, type v 11.2
42 lipodystrophy, congenital generalized, type 3 11.2
43 interstitial lung and liver disease 11.2
44 lipodystrophy, familial partial, type 6 11.2
45 fibrosis, neurodegeneration, and cerebral angiomatosis 11.2
46 lipid metabolism disorder 11.2
47 hyperlipidemia, familial combined, 2 11.1
48 neutral lipid storage disease with myopathy 11.1
49 aromatase deficiency 11.1
50 combined oxidative phosphorylation deficiency 16 11.1

Graphical network of the top 20 diseases related to Non-Alcoholic Fatty Liver Disease:



Diseases related to Non-Alcoholic Fatty Liver Disease

Symptoms & Phenotypes for Non-Alcoholic Fatty Liver Disease

Drugs & Therapeutics for Non-Alcoholic Fatty Liver Disease

Drugs for Non-Alcoholic Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 477)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Losartan Approved Phase 4 114798-26-4 3961
2
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
6
Insulin glulisine Approved Phase 4 207748-29-6
7
Liraglutide Approved Phase 4 204656-20-2 44147092
8
Glucagon Approved Phase 4 16941-32-5
9
Insulin aspart Approved Phase 4 116094-23-6 16132418
10
Insulin detemir Approved Phase 4 169148-63-4 5311023
11
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
12
Gliclazide Approved Phase 4 21187-98-4 3475
13
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
14
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
17
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
18
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
19
Tamoxifen Approved Phase 4 10540-29-1 2733526
20
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
21
Nortriptyline Approved Phase 4 72-69-5 4543
22
Ergotamine Approved Phase 4 113-15-5 8223
23
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
24
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
25
Zidovudine Approved Phase 4 30516-87-1 35370
26
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
27
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
28
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
29
Glimepiride Approved Phase 4 93479-97-1 3476
30
Phentermine Approved, Illicit Phase 4 122-09-8 4771
31
Aminolevulinic acid Approved Phase 4 106-60-5 137
32
Lenvatinib Approved, Investigational Phase 4 417716-92-8
33
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
34
Methyltestosterone Approved Phase 4 58-18-4 6010
35
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
36
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
37
Testosterone enanthate Approved Phase 4 315-37-7 9416
38
Empagliflozin Approved Phase 4 864070-44-0
39
Dulaglutide Approved, Investigational Phase 4 923950-08-7
40
Alogliptin Approved Phase 4 850649-61-5 11450633
41
Metformin Approved Phase 4 657-24-9 14219 4091
42
Zinc Approved, Investigational Phase 4 7440-66-6 32051
43
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
44
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
45
Insulin glargine Approved Phase 4 160337-95-1
46
Saxagliptin Approved Phase 4 361442-04-8 11243969
47
Ribavirin Approved Phase 4 36791-04-5 37542
48
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
49
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
50
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2

Interventional clinical trials:

(show top 50) (show all 1330)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
3 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
4 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
5 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
6 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
7 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
8 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
9 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
10 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
11 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
12 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
13 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
14 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
15 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
16 Treatment by Subcutaneous Continuous Infusion of Insulin by Portable Pump Versus Discontinuous Infusion of Insulin by Multi-injections in the Type 2 Diabetes: Study of the Insulinosensibility in the 2 Types of Treatments Unknown status NCT01889914 Phase 4 2 different procedures of administration of insulin
17 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
18 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
19 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
20 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
21 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
22 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
23 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
24 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
25 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
26 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
27 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
28 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
29 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
30 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
31 Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus Completed NCT01951651 Phase 4 Exenatide;Glipizide
32 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
33 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
34 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
35 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
36 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
37 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
38 Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus Completed NCT01432405 Phase 4 Exenatide;Pioglitazone
39 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
40 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
41 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
42 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
43 Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome Completed NCT01356394 Phase 4
44 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
45 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
46 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
47 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
48 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4 glucagon
49 A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
50 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin

Search NIH Clinical Center for Non-Alcoholic Fatty Liver Disease

Genetic Tests for Non-Alcoholic Fatty Liver Disease

Anatomical Context for Non-Alcoholic Fatty Liver Disease

MalaCards organs/tissues related to Non-Alcoholic Fatty Liver Disease:

40
Liver, Testes, Heart, Kidney, Endothelial, Ovary, Bone

Publications for Non-Alcoholic Fatty Liver Disease

Articles related to Non-Alcoholic Fatty Liver Disease:

(show top 50) (show all 16610)
# Title Authors PMID Year
1
Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. 61 46
20956972 2011
2
Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. 61 46
20497147 2010
3
Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. 61 46
19780876 2010
4
Transplantation of brown adipose tissue up-regulates miR-99a to ameliorate liver metabolic disorders in diabetic mice by targeting NOX4. 61
32000567 2020
5
Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease. 61
31852298 2020
6
Lack of association between early menopause and non-alcoholic fatty liver disease in postmenopausal women. 61
31538495 2020
7
Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. 61
31556117 2020
8
Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features. 61
31838461 2020
9
CHD is Associated With Higher Grades of NAFLD Predicted by Liver Stiffness. 61
31305280 2020
10
Aquaporin-9 is involved in the lipid-lowering activity of the nutraceutical silybin on hepatocytes through modulation of autophagy and lipid droplets composition. 61
31816412 2020
11
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). 61
31956725 2020
12
Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. 61
31865143 2020
13
San-Huang-Tang protects obesity/diabetes induced NAFLD by upregulating PGC-1α/PEPCK signaling in obese and galr1 knockout mice models. 61
31843573 2020
14
Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis. 61
32033763 2020
15
Recruitment and Retention of Patients for Nonalcoholic Steatohepatitis Clinical Trials. 61
32033759 2020
16
Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. 61
32033758 2020
17
Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis. 61
32033761 2020
18
Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. 61
32033762 2020
19
Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases. 61
31866404 2020
20
Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. 61
31764586 2020
21
Natural alkaloid and polyphenol compounds targeting lipid metabolism: Treatment implications in metabolic diseases. 61
31935398 2020
22
Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. 61
31690932 2020
23
The effects of hydroalcoholic extract of spinach on prevention and treatment of some metabolic and histologic features in a rat model of nonalcoholic fatty liver disease. 61
31849065 2020
24
Challenges and opportunities in drug development for nonalcoholic steatohepatitis. 61
31926994 2020
25
Crude extract of Camellia oleifera pomace ameliorates the progression of non-alcoholic fatty liver disease via decreasing fat accumulation, insulin resistance and inflammation. 61
31771682 2020
26
Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. 61
31882273 2020
27
Arterial and liver stiffness in patients with non-alcoholic fatty liver disease: hitting two targets with sodium-glucose co-transporter-2 inhibitors. 61
32011391 2020
28
Why Do Lifestyle Recommendations Fail in Most Patients with Nonalcoholic Fatty Liver Disease? 61
32033766 2020
29
Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Disease Burden Grows. 61
32033768 2020
30
Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. 61
31464779 2020
31
Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis. 61
31076404 2020
32
Protective effect of metformin against palmitate-induced hepatic cell death. 61
31786336 2020
33
Epidemiology of chronic liver diseases in the USA in the past three decades. 61
31366455 2020
34
Intermediary effect of inflammation on the association between dietary patterns and non-alcoholic fatty liver disease. 61
31809956 2020
35
Nonalcoholic Fatty Liver Disease. 61
32033769 2020
36
Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. 61
32033760 2020
37
Burden of Disease due to Nonalcoholic Fatty Liver Disease. 61
32033757 2020
38
Nutrition and Nonalcoholic Fatty Liver Disease: Current Perspectives. 61
32033765 2020
39
Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology? 61
31863731 2020
40
How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. 61
32033764 2020
41
New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. 61
32016853 2020
42
Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease. 61
31829750 2020
43
The influence of dietary fatty acids on liver fat content and metabolism. 61
30942685 2020
44
Diurnal Variation of Proton Density Fat Fraction in the Liver Using Quantitative Chemical Shift Encoded MRI. 61
31168893 2020
45
Role of ghrelin isoforms in the mitigation of hepatic inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress after bariatric surgery in rats. 61
31324878 2020
46
Association Between Dietary Selenium Intake and the Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. 61
31157605 2020
47
Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. 61
31612634 2020
48
In vitro and in vivo approaches for identifying the role of aryl hydrocarbon receptor in the development of nonalcoholic fatty liver disease. 61
31730885 2020
49
Associations of Liver Disease with Alcohol Use among People Living with HIV and the Role of Hepatitis C: The New Orleans Alcohol Use in HIV Study. 61
31812989 2020
50
C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes. 61
31351021 2020

Variations for Non-Alcoholic Fatty Liver Disease

ClinVar genetic disease variations for Non-Alcoholic Fatty Liver Disease:

6 (show all 46) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PNPLA3 NM_025225.3(PNPLA3):c.444C>G (p.Ile148Met)SNV drug response 341932 rs738409 22:44324727-44324727 22:43928847-43928847
2 PNPLA3 NM_025225.3(PNPLA3):c.414C>T (p.Val138=)SNV Uncertain significance 341931 rs768191646 22:44323041-44323041 22:43927161-43927161
3 PNPLA3 NM_025225.3(PNPLA3):c.*141T>GSNV Uncertain significance 341951 rs886057602 22:44342403-44342403 22:43946523-43946523
4 PNPLA3 NM_025225.3(PNPLA3):c.*989dupduplication Uncertain significance 341959 rs3083314 22:44343239-44343240 22:43947359-43947360
5 PNPLA3 NM_025225.3(PNPLA3):c.*1068C>TSNV Uncertain significance 341963 rs746640250 22:44343330-44343330 22:43947450-43947450
6 PNPLA3 NM_025225.3(PNPLA3):c.-44C>GSNV Uncertain significance 341924 rs773713393 22:44319748-44319748 22:43923868-43923868
7 PNPLA3 NM_025225.3(PNPLA3):c.1209C>T (p.Pro403=)SNV Uncertain significance 341942 rs184910573 22:44340667-44340667 22:43944787-43944787
8 PNPLA3 NM_025225.3(PNPLA3):c.1340G>A (p.Arg447Gln)SNV Uncertain significance 341944 rs147289545 22:44342156-44342156 22:43946276-43946276
9 PNPLA3 NM_025225.3(PNPLA3):c.*19T>GSNV Uncertain significance 341948 rs569255289 22:44342281-44342281 22:43946401-43946401
10 PNPLA3 NM_025225.3(PNPLA3):c.*71T>GSNV Uncertain significance 341950 rs886057601 22:44342333-44342333 22:43946453-43946453
11 PNPLA3 NM_025225.3(PNPLA3):c.646A>C (p.Thr216Pro)SNV Uncertain significance 341935 rs35726887 22:44328917-44328917 22:43933037-43933037
12 PNPLA3 NM_025225.3(PNPLA3):c.659A>G (p.Tyr220Cys)SNV Uncertain significance 341936 rs143392071 22:44328930-44328930 22:43933050-43933050
13 PNPLA3 NM_025225.3(PNPLA3):c.980-14A>CSNV Uncertain significance 341939 rs781212740 22:44335859-44335859 22:43939979-43939979
14 PNPLA3 NM_025225.3(PNPLA3):c.1112+14G>ASNV Uncertain significance 341941 rs138736228 22:44336019-44336019 22:43940139-43940139
15 PNPLA3 NM_025225.3(PNPLA3):c.216T>C (p.Leu72=)SNV Uncertain significance 341927 rs147412464 22:44322843-44322843 22:43926963-43926963
16 PNPLA3 NM_025225.3(PNPLA3):c.1419C>T (p.Pro473=)SNV Uncertain significance 341947 rs376208148 22:44342235-44342235 22:43946355-43946355
17 PNPLA3 NM_025225.3(PNPLA3):c.*960T>GSNV Uncertain significance 341958 rs886057603 22:44343222-44343222 22:43947342-43947342
18 PNPLA3 NM_025225.3(PNPLA3):c.*987_*989dupduplication Uncertain significance 341961 rs3083314 22:44343239-44343240 22:43947359-43947360
19 PNPLA3 NM_025225.3(PNPLA3):c.*1175A>CSNV Uncertain significance 341966 rs529050829 22:44343437-44343437 22:43947557-43947557
20 PNPLA3 NM_025225.3(PNPLA3):c.*626A>GSNV Uncertain significance 341953 rs564752977 22:44342888-44342888 22:43947008-43947008
21 PNPLA3 NM_025225.3(PNPLA3):c.*990T>ASNV Uncertain significance 341962 rs886057604 22:44343252-44343252 22:43947372-43947372
22 PNPLA3 NM_025225.3(PNPLA3):c.*1076C>TSNV Uncertain significance 341964 rs886057605 22:44343338-44343338 22:43947458-43947458
23 PNPLA3 NM_025225.3(PNPLA3):c.-40C>GSNV Likely benign 341925 rs144821153 22:44319752-44319752 22:43923872-43923872
24 PNPLA3 NM_025225.3(PNPLA3):c.295T>G (p.Cys99Gly)SNV Likely benign 341928 rs2076213 22:44322922-44322922 22:43927042-43927042
25 PNPLA3 NM_025225.3(PNPLA3):c.343G>T (p.Gly115Cys)SNV Likely benign 341930 rs2076212 22:44322970-44322970 22:43927090-43927090
26 PNPLA3 NM_025225.3(PNPLA3):c.561C>T (p.Phe187=)SNV Likely benign 341934 rs34179073 22:44328832-44328832 22:43932952-43932952
27 PNPLA3 NM_025225.3(PNPLA3):c.*63C>TSNV Likely benign 341949 rs2294919 22:44342325-44342325 22:43946445-43946445
28 PNPLA3 NM_025225.3(PNPLA3):c.*747T>ASNV Likely benign 341956 rs62228000 22:44343009-44343009 22:43947129-43947129
29 PNPLA3 NM_025225.3(PNPLA3):c.1300A>G (p.Lys434Glu)SNV Likely benign 341943 rs2294918 22:44342116-44342116 22:43946236-43946236
30 PNPLA3 NM_025225.3(PNPLA3):c.*691_*692dupduplication Likely benign 341954 rs397716964 22:44342941-44342942 22:43947061-43947062
31 PNPLA3 NM_025225.3(PNPLA3):c.*889A>GSNV Likely benign 341957 rs1810508 22:44343151-44343151 22:43947271-43947271
32 PNPLA3 NM_025225.3(PNPLA3):c.*988_*989dupduplication Likely benign 341960 rs3083314 22:44343239-44343240 22:43947359-43947360
33 PNPLA3 NM_025225.3(PNPLA3):c.*1090A>GSNV Likely benign 341965 rs9626058 22:44343352-44343352 22:43947472-43947472
34 PNPLA3 NM_025225.2(PNPLA3):c.-168C>ASNV Likely benign 341921 rs140746182 22:44319624-44319624 22:43923744-43923744
35 PNPLA3 NM_025225.3(PNPLA3):c.187+12G>ASNV Likely benign 341926 rs116795637 22:44319990-44319990 22:43924110-43924110
36 PNPLA3 NM_025225.3(PNPLA3):c.1358G>T (p.Ser453Ile)SNV Likely benign 341945 rs6006460 22:44342174-44342174 22:43946294-43946294
37 PNPLA3 NM_025225.3(PNPLA3):c.980-15A>CSNV Likely benign 341938 rs144872932 22:44335858-44335858 22:43939978-43939978
38 PNPLA3 NM_025225.3(PNPLA3):c.992A>G (p.Glu331Gly)SNV Likely benign 341940 rs144233415 22:44335885-44335885 22:43940005-43940005
39 PNPLA3 NM_025225.2(PNPLA3):c.-112A>TSNV Likely benign 341922 rs531789428 22:44319680-44319680 22:43923800-43923800
40 PNPLA3 NM_025225.2(PNPLA3):c.-111G>ASNV Likely benign 341923 rs548897706 22:44319681-44319681 22:43923801-43923801
41 PNPLA3 NM_025225.3(PNPLA3):c.*707T>CSNV Likely benign 341955 rs2008451 22:44342969-44342969 22:43947089-43947089
42 PNPLA3 NM_025225.3(PNPLA3):c.*429T>CSNV Likely benign 341952 rs41278873 22:44342691-44342691 22:43946811-43946811
43 PNPLA3 NM_025225.3(PNPLA3):c.447C>T (p.Pro149=)SNV Likely benign 341933 rs738408 22:44324730-44324730 22:43928850-43928850
44 PNPLA3 NM_025225.3(PNPLA3):c.972C>T (p.Leu324=)SNV Benign/Likely benign 341937 rs116679026 22:44333145-44333145 22:43937265-43937265
45 PNPLA3 NM_025225.3(PNPLA3):c.309G>A (p.Pro103=)SNV Benign/Likely benign 341929 rs79118505 22:44322936-44322936 22:43927056-43927056
46 PNPLA3 NM_025225.3(PNPLA3):c.1359C>G (p.Ser453Arg)SNV Benign/Likely benign 341946 rs76510336 22:44342175-44342175 22:43946295-43946295

Cosmic variations for Non-Alcoholic Fatty Liver Disease:

9 (show top 50) (show all 15626)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 30
2 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 30
3 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 30
4 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 30
5 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 30
6 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 30
7 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 30
8 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 30
9 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 30
10 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 30
11 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 30
12 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 30
13 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 30
14 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 30
15 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 30
16 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 30
17 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 30
18 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 30
19 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 30
20 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 30
21 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 30
22 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 30
23 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 30
24 COSM92703312 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 30
25 COSM92032561 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221= 14:67807621-67807621 30
26 COSM84360265 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.1979+14C>A p.? 5:32395145-32395145 30
27 COSM84362097 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 30
28 COSM85178149 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 30
29 COSM87884183 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 30
30 COSM127392053 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 30
31 COSM149268658 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 30
32 COSM149328017 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 30
33 COSM149281099 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 30
34 COSM144309108 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 30
35 COSM87420403 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 30
36 COSM98996636 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 30
37 COSM92255466 ZC3H15 liver,NS,carcinoma,hepatocellular carcinoma c.*55T>G p.? 2:186508788-186508788 30
38 COSM85044193 ZC3H14 liver,NS,carcinoma,hepatocellular carcinoma c.*10873G>A p.? 14:88622624-88622624 30
39 COSM106743522 ZBTB7B liver,NS,carcinoma,hepatocellular carcinoma c.*635G>C p.? 1:155017320-155017320 30
40 COSM93795261 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 30
41 COSM103188148 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 30
42 COSM91488114 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 30
43 COSM95291738 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 30
44 COSM107993551 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2383A>G p.I795V 8:80519295-80519295 30
45 COSM107993152 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2208A>G p.T736= 8:80518852-80518852 30
46 COSM86073785 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 30
47 COSM142300159 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1580A>G p.N527S 8:63187582-63187582 30
48 COSM90849676 YOD1 liver,NS,carcinoma,hepatocellular carcinoma c.*157T>C p.? 1:207048863-207048863 30
49 COSM90620829 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 30
50 COSM86902201 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167= 3:183722100-183722100 30

Expression for Non-Alcoholic Fatty Liver Disease

Search GEO for disease gene expression data for Non-Alcoholic Fatty Liver Disease.

Pathways for Non-Alcoholic Fatty Liver Disease

Pathways related to Non-Alcoholic Fatty Liver Disease according to KEGG:

36
# Name Kegg Source Accession
1 Non-alcoholic fatty liver disease (NAFLD) hsa04932
2 Glycerolipid metabolism hsa00561

Pathways related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.85 MIR34A MIR29C MIR27B MIR27A MIR26A1 MIR21
2 10.77 MIR200B MIR200A MIR107

GO Terms for Non-Alcoholic Fatty Liver Disease

Cellular components related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.4 MIR378A MIR29C MIR27B MIR27A MIR26A1 MIR22

Biological processes related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 MIR34A MIR27B MIR21 MIR140 MIR132
2 positive regulation of angiogenesis GO:0045766 9.85 MIR378A MIR27B MIR21 MIR132
3 negative regulation of cell migration GO:0030336 9.84 MIR34A MIR29C MIR26A1 MIR21
4 negative regulation of angiogenesis GO:0016525 9.8 MIR34A MIR29C MIR21 MIR200B
5 cholesterol homeostasis GO:0042632 9.79 MIR34A MIR27B MIR132
6 negative regulation of gene expression GO:0010629 9.76 MSR1 MIR33A MIR29C MIR27B MIR27A MIR21
7 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.75 MIR29C MIR26A1 MIR21
8 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.73 MIR29C MIR26A1 MIR22
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 MIR27B MIR27A MIR26A1 MIR21
10 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.67 MIR27B MIR27A MIR132 MIR10B
11 negative regulation of vascular endothelial cell proliferation GO:1905563 9.65 MIR34A MIR29C MIR132
12 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.63 MIR26A1 MIR21
13 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.63 MIR29C MIR26A1
14 positive regulation of vascular endothelial cell proliferation GO:1905564 9.63 MIR27A MIR21 MIR132
15 positive regulation of cellular senescence GO:2000774 9.62 MIR34A MIR22
16 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.62 MIR27B MIR27A
17 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.62 MIR27B MIR27A MIR132 MIR10B
18 negative regulation of nitric-oxide synthase activity GO:0051001 9.61 MIR26A1 MIR132
19 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.61 MIR34A MIR21 MIR140
20 negative regulation of cell cycle G1/S phase transition GO:1902807 9.6 MIR29C MIR26A1
21 positive regulation of smooth muscle cell differentiation GO:0051152 9.58 MIR34A MIR22
22 regulation of cholesterol esterification GO:0010872 9.57 MIR27B MIR27A
23 negative regulation of cholesterol efflux GO:0090370 9.56 MIR33A MIR27B MIR27A MIR26A1
24 negative regulation of monooxygenase activity GO:0032769 9.52 MIR378A MIR27B
25 negative regulation of lipid binding GO:1900131 9.51 MIR27B MIR27A
26 miRNA mediated inhibition of translation GO:0035278 9.5 MIR378A MIR27B MIR27A MIR21 MIR200B MIR132
27 gene silencing by miRNA GO:0035195 9.5 MIR378A MIR34A MIR33A MIR29C MIR27B MIR27A

Molecular functions related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIR378A MIR34A MIR33A MIR29C MIR27B MIR27A
2 RNA polymerase II complex binding GO:0000993 9.13 MIR378A MIR33A MIR140

Sources for Non-Alcoholic Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....